{"id":727203,"date":"2023-01-31T08:56:56","date_gmt":"2023-01-31T13:56:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/"},"modified":"2023-01-31T08:56:56","modified_gmt":"2023-01-31T13:56:56","slug":"evolus-to-participate-in-the-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/","title":{"rendered":"Evolus to Participate in the SVB Securities Global Biopharma Conference"},"content":{"rendered":"

<\/p>\n

Evolus to Participate in the <\/b>SVB Securities Global Biopharma Conference<\/b><\/p>\n

NEWPORT BEACH, Calif.–(BUSINESS WIRE<\/a>)–
\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference.\n<\/p>\n\n\n\n\n
\n

Event:<\/b><\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nSVB Securities Global Biopharma Conference.\n<\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nTuesday, February 14, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

Time:<\/b><\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11:20-11:50 am ET\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAn audio webcast of this event will be available on the investor relations section of Evolus\u2019 website at www.evolus.com<\/a>. A replay of the webcast will be available for 90 days after the date of the presentation.\n<\/p>\n

About Evolus, Inc.<\/b><\/p>\n

\nEvolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau\u00ae<\/sup> (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure\u2122 technology. Visit us at www.evolus.com<\/a> and follow us on LinkedIn<\/a>, Twitter<\/a>, Instagram<\/a> or Facebook<\/a>.\n<\/p>\n

\nJeuveau\u00ae<\/sup> is a registered trademark of Evolus, Inc.
\n
Hi-Pure\u2122<\/sup> is a trademark of Daewoong Pharmaceutical Co, Ltd.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230131005470\/en\/<\/a><\/span><\/p>\n

Investor\/Media Contact:
\n<\/span>
David K. Erickson, Evolus, Inc.
\n
Vice President, Investor Relations
\n
Tel: 949-966-1798
\n
Email: david.erickson@evolus.com<\/a><\/p>\n

Media Contact<\/span>:
\n
Email: media@evolus.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Cosmetics Retail Health General Health Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Evolus to Participate in the SVB Securities Global Biopharma Conference NEWPORT BEACH, Calif.–(BUSINESS WIRE)– Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference. Event: \u00a0 SVB Securities Global Biopharma Conference. Date: \u00a0 Tuesday, February 14, 2023 Time: \u00a0 11:20-11:50 am ET An audio webcast of this event will be available on the investor relations section of Evolus\u2019 website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for … <\/p>\n

Continue reading “Evolus to Participate in the SVB Securities Global Biopharma Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727203","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEvolus to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evolus to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Evolus to Participate in the SVB Securities Global Biopharma Conference NEWPORT BEACH, Calif.–(BUSINESS WIRE)– Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference. Event: \u00a0 SVB Securities Global Biopharma Conference. Date: \u00a0 Tuesday, February 14, 2023 Time: \u00a0 11:20-11:50 am ET An audio webcast of this event will be available on the investor relations section of Evolus\u2019 website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for … Continue reading "Evolus to Participate in the SVB Securities Global Biopharma Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T13:56:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evolus to Participate in the SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-01-31T13:56:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\",\"name\":\"Evolus to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-01-31T13:56:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evolus to Participate in the SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evolus to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Evolus to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk","og_description":"Evolus to Participate in the SVB Securities Global Biopharma Conference NEWPORT BEACH, Calif.–(BUSINESS WIRE)– Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference. Event: \u00a0 SVB Securities Global Biopharma Conference. Date: \u00a0 Tuesday, February 14, 2023 Time: \u00a0 11:20-11:50 am ET An audio webcast of this event will be available on the investor relations section of Evolus\u2019 website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for … Continue reading \"Evolus to Participate in the SVB Securities Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-31T13:56:56+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evolus to Participate in the SVB Securities Global Biopharma Conference","datePublished":"2023-01-31T13:56:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/","name":"Evolus to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-01-31T13:56:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005470r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evolus-to-participate-in-the-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evolus to Participate in the SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727203"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}